ByteDance AI Drug Discovery Unit Seeks Independent Funding
ByteDance is spinning off its AI drug discovery business into a separate entity and initiating an independent financing process, marking a major step toward commercializing its artificial intelligence capabilities in life sciences. Following the spin-off, ByteDance will retain majority control of the new company. The core AI drug discovery team, comprising approximately 50 members led by Liu Kai and consisting of AI4S algorithm specialists and senior pharmaceutical researcher
ByteDance is separating its artificial intelligence drug discovery operations into a new, independently financed company. While ByteDance will maintain majority ownership, the dedicated AI drug discovery team will move to the new entity. This unit, which began in 2021, has developed advanced AI models for molecular structure prediction and protein binder design.
Recent advancements include breakthroughs in predicting protein-ligand structures and designing novel molecules. The platform has also achieved a significant milestone by developing a single small molecule capable of blocking all three IL-17 family dimer isoforms, a key target for autoimmune diseases. The company's Anew Labs platform has published research on various aspects of AI-driven drug discovery, with early projects focusing on IL17 and IL4R targets.
This spin-off signifies a move towards commercializing AI in the life sciences sector, indicating growing industry confidence in AI's transition from research to practical drug development applications.
📌 Kaynak
Bu özet Pandaily kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →